Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASAP: Ferric Carboxymaltose vs Oral Iron in Pregnant Women with IDA
NCT01131624Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- May 2010
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by CSL Vifor. Primary endpoint: Average Hb increase after 3 weeks. Started May 2010; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT01131624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131624.